Temporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutation

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Gong, Belvin ^a,b   Kielar, Catherine ^a   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; PROTEASOME; UBIQUITIN;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GENE; GENE MUTATION; HTT GENE; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL; NERVOUS SYSTEM PARAMETERS; NEURONAL INTRANUCLEAR INCLUSIONS; NONHUMAN; PROTEIN AGGREGATION; TRANSGENIC MOUSE; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION;

ANIMALS; FEMALE; HUNTINGTON DISEASE; INCLUSION BODIES; MALE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITINATED PROTEINS; UBIQUITINATION;

MUS; MUS MUSCULUS;

EID: 84864233715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041450     Document Type: Article

References (76)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
2. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
3. Roizin L, Stellar S, Liu JC, (1979) Neuronal nuclear-cytoplasmic changes in Huntington's chorea: electron microscope investigations. In Chase TN, Wexler NS and Barbeau A, eds. Advances in Neurology, Huntington's Disease. New York, NY: Raven Press 95-122.
4. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
5. Yamada M, Sato T, Tsuji S, Takahashi H, (2008) CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol 115: 71-86.
6. Gil JM, Rego AC, (2009) The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev 59: 410-431.
7. Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, et al. (1997) Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91: 753-763.
8. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, et al. (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7: 783-790.
9. Rubinsztein DC, Wyttenbach A, Rankin J, (1999) Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? J Med Genet 36: 265-270.
10. Rankin J, Wyttenbach A, Rubinsztein DC, (2003) Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem J 15: 15-19.
11. Sánchez I, Mahlke C, Yuan J, (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421: 373-379.
12. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, et al. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10: 148-154.
13. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W,et al. ()2007 A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci USA 104: 16685-16689.
14. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, et al. (2008) Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 30: 293-302.
15. Saudou F, Finkbeiner S, Devys D, Greenberg ME, (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66.
16. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19: 2522-2534.
17. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, et al. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46: 842-849.
18. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, et al. (2001) Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 14: 1492-1504.
19. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S, (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810.
20. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, et al. (2005) Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 102: 11402-1407.
21. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, et al. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA 103: 4246-4251.
22. Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ, (2008) Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull 75: 146-157.
23. Zuchner T, Brundin P, (2008) Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ 15: 435-442.
24. Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, et al. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 33: 331-341.
25. Morton AJ, Lagan MA, Skepper JN, Dunnett SB, (2000) Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 29: 679-702.
26. Maat-Schieman M, Roos R, Losekoot M, Dorsman J, Welling-Graafland C, et al. (2007) Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol 17: 31-37.
27. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, et al. (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18: 150-154.
28. Herndon ES, Hladik CL, Shang P, Burns DK, Raisanen J, et al. (2009) Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J Neuropathol Exp Neurol 68: 250-261.
29. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, et al. (2004) Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 13: 1803-1813.
30. Wanderer J, Morton AJ, (2007) Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease. Histochem Cell Biol 127: 473-484.
31. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL, (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67: 1159-1165.
32. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
33. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19: 3248-3257.
34. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, et al. (1999) discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19: 10428-10437.
35. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, et al. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20: 5115-5123.
36. Gibson HE, Reim K, Brose N, Morton AJ, Jones S, (2005) A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur J Neurosci 22: 1701-1712.
37. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97: 6809-6814.
38. Ko J, Ou S, Patterson PH, (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 56: 319-329.
39. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285: 8808-8823.
40. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, et al. (2010) Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci 30: 10541-10550.
41. Chen S, Berthelier V, Yang W, Wetzel R, (2001) Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311: 173-182.
42. Meade CA, Deng YP, Fusco FR, Del Mar N, Hersch S, et al. (2002) Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J Comp Neurol 449: 241-269.
43. Cajavec B, Bernard S, Herzel H, (2005) Aggregation in Huntington's disease: insights through modelling. Genome Inform 16: 262-271.
44. Poirier MA, Jiang H, Ross CA, (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum Mol Genet 14: 765-774.
45. Zhang QC, Yeh TL, Leyva A, Frank LG, Miller J, et al. (2011) A compact beta model of huntingtin toxicity. J Biol Chem 286: 8188-8196.
46. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, et al. (1996) Expression of normal and mutant huntingtin in the developing brain. J Neurosci 16: 5523-5535.
47. Southwell AL, Patterson PH, (2010) Antibody therapy in neurodegenerative disease. Rev Neurosci 21: 273-287.
48. Koo EH, Lansbury PT, Kelly JW, (1999) Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96: 9989-9990.
49. Ferrone F, (1999) Analysis of protein aggregation kinetics. Methods Enzymol 309: 256-274.
50. Wetzel R, (2006) Nucleation of huntingtin aggregation in cells. Nat Chem Biol 2: 297-298.
51. Colby DW, Cassady JP, Lin GC, Ingram VM, Wittrup KD, (2006) Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol 2: 319-323.
52. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, et al. (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19: 1189-1202.
53. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, et al. (1995) Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14: 1065-1074.
54. Kung VW, Hassam R, Morton AJ, Jones S, (2007) Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 146: 1571-1580.
55. Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, et al. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969.
56. Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, et al. (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29: 10371-10386.
57. André VM, Cepeda C, Fisher YE, Huynh M, Bardakjian N, et al. (2011) Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 31: 1170-1182.
58. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280: 556-563.
59. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567.
60. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 28: 6182-6195.
61. Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, et al. (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 22: 8266-8276.
62. Senut MC, Suhr ST, Kaspar B, Gage FH, (2000) Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 20: 219-229.
63. Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 10: 1829-1845.
64. Wexler NS, Young AB, Tanzi RE, Travers H, Starosta-Rubinstein S, et al. (1987) Homozygotes for Huntington's disease. Nature 326: 194-197.
65. Myers RH, Leavitt J, Farrer LA, Jagadeesh J, McFarlane H, et al. (1989) Homozygote for Huntington disease. Am J Hum Genet 45: 615-618.
66. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, et al. (1994) A worldwide study of the Huntington's disease mutation. N Engl J Med 330: 1401-1416.
67. Durr A, Hahn-Barma V, Brice A, Pêcheux C, Dodé C, et al. (1999) Homozygosity in Huntington's disease. J Med Genet 36: 172-173.
68. Laccone F, Engel U, Holinski-Feder E, Weigell-Weber M, Marczinek K, et al. (1999) DNA analysis of Huntington's disease. Five years of experience in Germany, Austria, and Switzerland. Neurology 53: 801-806.
69. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, et al. (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126: 946-955.
70. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, et al. (1996) Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 271: 19385-19394.
71. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, et al. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448: 704-708.
72. Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, et al. (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 24: 217-233.
73. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D, (1999) Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci USA 96: 11404-11409.
74. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743.
75. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, et al. (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9: 2197-2202.
76. Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291: 2423-2428.